Coya Therapeutics, Inc. · NASDAQ:COYA
Coya Therapeutics — Investor Presentation (July 2026)
18 slides from Coya Therapeutics's investor presentation, July 2026
Slide 1: Combating Neurodegeneration Via Treg Directed Combination Therapy
Combating Neurodegeneration Via Treg Directed Combination Therapy Investor Overview July 2026
Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers
Cautionary Note of Forward-Looking Statements and Disclaimers in this Presentation This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-lo
Slide 3: Coya Therapeutics (COYA): Investment Highlights
Coya Therapeutics (COYA): Investment Highlights Indications With High Unmet Need • ALS, Frontotemporal Dementia (FTD), Alzheimer's Disease (AD) • De-risked approach with regulatory flexibility Novel Combination Therapies • COYA 302 (ALS, FTD) and COYA 303 (AD) have differentiated approach targeting
Slide 4: Key Catalysts and Milestones
Key Catalysts and Milestones COYA 302 in ALS: • Complete enrollment: expected 2H 2026 ALSTARS (Phase 2) • Top-line data: expected 1Q 2027 • Management to provide periodic updates COYA 302 in FTD: • Acceptance of IND: accepted 1Q 2026 • initiate Phase 2a study: expected 2H 2026 Translational Datasets
Slide 5: LD IL-2 Combination Therapy: Pillars For Success
LD IL-2 Combination Therapy: 3 Pillars For Success The neurodegeneration field increasingly recognizes combination-based therapeutic strategies such as Coya's as a viable path forward for diseases driven by complex, multifactorial biology Differentiated Combination- Validated Science Early Clinical
Slide 6: COYA 302 in ALS & FTD
COYA 302 in ALS & FTD Proprietary, Recombinant Human Low Dose Interleukin-2 (LD rhIL-2) and CTLA4-Ig
Slide 7: COYA 302 in ALS and FTD
COYA 302 in ALS and FTD ALS and Frontotemporal Dementia • High unmet need • Relatively short life expectancy from time of diagnosis • Significant loss of QoL • Orphan diseases • Flexible and fast paths to regulatory approval • ALS: ~33,000 patients in U.S. (NIH) • FTD: 50,000-60,000 patients in U.S.
Slide 8: COYA 302: Combo Therapies Enhance Treg Function
COYA 302: Combo Therapies Enhance Treg Function Dysfunctional immuno-regulatory environment due to inflammation Restoring Immune Regulation via Combination Therapy • Inflammation creates a dysfunctional immuno- regulatory environment o Tregs are dysregulated and dysfunctional Dysfunctional Tregs CD8
Slide 9: COYA 302 in ALS
COYA 302 in ALS
Slide 10: Current ALS Therapies aim to slow disease progression
Current ALS Therapies aim to slow disease progression Many companies have garnered significant value by PRO-ACT ALS Database Mean (SD) Documented demonstrating Decline (ALSFRS-R) a limited` benefit of slowing the rate of ALS progression 2 3 Baseline 4 8 12 16 20 24 Weeks ALS patients average rate of
Slide 11: LD IL-2 + CTLA4-Ig IIT: Signal in Mild-to-Moderate ALS
LD IL-2 + CTLA4-Ig IIT: Signal in Mild-to-Moderate ALS ALSFRS-R improved or stabilized over 6 CTLA-4 Ig + LD IL-2 ameliorates progression months in a 48 week IST in ALS Patients Mean (±SD) ALSFRS-R Score (N=4) 48 44 33.5 33.75 32 30 40 36 ALSFRS-R Score 32 28 24 20 16 12 48-Week Treatment Follow-Up
Slide 12: COYA 302: ALSTARS Phase 2 Study in ALS Ongoing
COYA 302: ALSTARS Phase 2 Study in ALS Ongoing Key Inclusion Criteria Primary Endpoint Randomized, Double-Blind, Placebo-Controlled Change in disease • Diagnosis of sporadic or Phase 2 Study with Blinded Active Extension severity over time familial ALS measured by ALSFRS-R • ALSFR-R score ≥ 35 at 4
Slide 13: COYA 302 in FTD
COYA 302 in FTD
Slide 14: LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD
LD IL-2 & CTLA-4 Ig: Signal in Mild-to-Moderate FTD Encouraging clinical data in FTD in Investigator Sponsored Study • Treg suppressive function and percentage: o Increased after first treatment o Remained elevated across 22-week treatment period Increased Treg Suppressive Function Expansion of Treg
Slide 15: LD IL-2 & CTLA-4 Ig: Signal in FTD – cont.
LD IL-2 & CTLA-4 Ig: Signal in FTD – cont. Cognitive Stability in 22-Week Investigator Sponsored Study • CDR‐FTLD, MoCA, PASS cognitive tests exhibited no cognitive decline at end of study compared with baseline Moca Scores Remains CDR-FTLD Scores Remains Unchanged Compared to Unchanged Compared to
Slide 16: COYA-302 in FTD: Phase 2a Expected 2H 2026 Start
COYA-302 in FTD: Phase 2a Expected 2H 2026 Start Primary Endpoint Randomized, Double-Blind, Placebo-Controlled • Safety and Phase 2a Study with Open Label Extension tolerability Key Inclusion Criteria 4 wk. 24 wk. Double Blind 24 week Open Label Clinical Efficacy • Non-Fluent Primary Screening Treat
Slide 17: Coya's Late Stage Neurodegenerative Pipeline
Coya's Late Stage Neurodegenerative Pipeline Product IND-Enabling Phase 1 Phase 2 Phase 3 Partner Dr. Reddy’s Labs COYA 302 (worldwide, Low Dose IL-2 + ALS (Amyotrophic Lateral Sclerosis) excl. Japan & CTLA4-Ig LatAm) FTD (Frontotemporal Dementia) Coya retains worldwide rights COYA 303 Alzheimer's D
Slide 18: Thank You!
THERAPEUTICS Thank You! ,
Coya Therapeutics — Investor Presentation (July 2026) on 6ix